Drugs / AST-301
AST-301
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00436254 | Oct 2001 → Mar 2010 | HER2 positive breast carcinoma, female breast carcinoma, ovarian carcinoma, ovarian germ cell tumor | University of Washington | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05771584 | Jul 2023 → Oct 2025 overdue | gastric cancer | Aston Sci. Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05163223 | Feb 2022 → May 2024 | breast cancer | Aston Sci. Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AST-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05771584 ↗ |
| Known as | AST-301(pNGVL3-hICD) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05163223 ↗ |
| Known as | pNGVL3-hICD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00436254 ↗ |
| Modality | Vaccine | “This is a dose-escalation study of a plasmid-based DNA (pNGVL3-hICD) vaccine.” NCT00436254 ↗ |
| Route | Other | “Intradermal injection” NCT05163223 ↗ |
| Target | ERBB2 | “a plasmid-based vaccine encoding the ERBB2 intracellular domain” PMID 36326756 ↗ Jan 2023 |